Fulgent Genetics (NASDAQ:FLGT - Get Free Report) updated its FY24 earnings guidance on Friday. The company provided earnings per share guidance of $0.33 for the period, compared to the consensus earnings per share estimate of ($0.39). Fulgent Genetics also updated its FY 2024 guidance to 0.330-0.330 EPS.
Fulgent Genetics Price Performance
NASDAQ:FLGT traded down $2.89 during trading hours on Friday, reaching $19.13. 359,295 shares of the company were exchanged, compared to its average volume of 178,543. Fulgent Genetics has a 52-week low of $18.76 and a 52-week high of $30.68. The stock has a 50 day simple moving average of $21.08 and a 200 day simple moving average of $21.44. The firm has a market cap of $579.64 million, a price-to-earnings ratio of -3.62 and a beta of 1.51.
Insider Activity
In other news, CEO Ming Hsieh sold 2,313 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $52,805.79. Following the transaction, the chief executive officer now directly owns 707,275 shares of the company's stock, valued at approximately $16,147,088.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 4,324 shares of company stock worth $98,717. 32.66% of the stock is currently owned by corporate insiders.
About Fulgent Genetics
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Recommended Stories
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
